Efficacy and safety of sorafenib for advanced renal cell carcinoma: Real-world data of patients with renal impairment

Katsunori Tatsugami, Mototsugu Oya, Koki Kabu, Hideyuki Akaza

研究成果: Article

5 引用 (Scopus)

抄録

Background: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. Methods: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m2. Background factors considered to affect prognosis were well balanced by propensity score matching between the groups. Demographics, dose modification, adverse events, tumour response, progression-free survival, and renal function (eGFR) were evaluated. Results: Among 935 and 2008 patients with an eGFR of < 45 and ≥45, respectively, 613 pairs were matched. The mean starting dose was significantly lower in patients with an eGFR of < 45; however, the mean daily dose, median treatment duration, progression-free survival, and tumour response were similar between the groups. In terms of safety, no significant differences were found in serious adverse events, although cytopaenia (16.6% vs 10.6%) and renal dysfunction (4.4% vs 0.7%) were higher in patients with an eGFR of < 45 than ≥45 in all adverse events. There were also no differences in dose modification, including dose reduction, dose interruption, and treatment discontinuation. Conclusion: Throughout the 12-month observation period, sorafenib in patients with an eGFR of < 45 and ≥45 showed similar safety and efficacy, and treatment was continued without affecting renal function.

元の言語English
ページ(範囲)19406-19414
ページ数9
ジャーナルOncotarget
9
発行部数27
DOI
出版物ステータスPublished - 2018 4 10

Fingerprint

Glomerular Filtration Rate
Renal Cell Carcinoma
Kidney
Safety
Disease-Free Survival
Propensity Score
sorafenib
Neoplasms
Observation
Demography
Therapeutics

ASJC Scopus subject areas

  • Oncology

これを引用

Efficacy and safety of sorafenib for advanced renal cell carcinoma : Real-world data of patients with renal impairment. / Tatsugami, Katsunori; Oya, Mototsugu; Kabu, Koki; Akaza, Hideyuki.

:: Oncotarget, 巻 9, 番号 27, 10.04.2018, p. 19406-19414.

研究成果: Article

Tatsugami, Katsunori ; Oya, Mototsugu ; Kabu, Koki ; Akaza, Hideyuki. / Efficacy and safety of sorafenib for advanced renal cell carcinoma : Real-world data of patients with renal impairment. :: Oncotarget. 2018 ; 巻 9, 番号 27. pp. 19406-19414.
@article{a4e4d2b505054603b935f5d91d772ab2,
title = "Efficacy and safety of sorafenib for advanced renal cell carcinoma: Real-world data of patients with renal impairment",
abstract = "Background: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. Methods: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m2. Background factors considered to affect prognosis were well balanced by propensity score matching between the groups. Demographics, dose modification, adverse events, tumour response, progression-free survival, and renal function (eGFR) were evaluated. Results: Among 935 and 2008 patients with an eGFR of < 45 and ≥45, respectively, 613 pairs were matched. The mean starting dose was significantly lower in patients with an eGFR of < 45; however, the mean daily dose, median treatment duration, progression-free survival, and tumour response were similar between the groups. In terms of safety, no significant differences were found in serious adverse events, although cytopaenia (16.6{\%} vs 10.6{\%}) and renal dysfunction (4.4{\%} vs 0.7{\%}) were higher in patients with an eGFR of < 45 than ≥45 in all adverse events. There were also no differences in dose modification, including dose reduction, dose interruption, and treatment discontinuation. Conclusion: Throughout the 12-month observation period, sorafenib in patients with an eGFR of < 45 and ≥45 showed similar safety and efficacy, and treatment was continued without affecting renal function.",
keywords = "Advanced RCC, EGFR, Propensity score matching, Real-world data, Sorafenib",
author = "Katsunori Tatsugami and Mototsugu Oya and Koki Kabu and Hideyuki Akaza",
year = "2018",
month = "4",
day = "10",
doi = "10.18632/oncotarget.24779",
language = "English",
volume = "9",
pages = "19406--19414",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - Efficacy and safety of sorafenib for advanced renal cell carcinoma

T2 - Real-world data of patients with renal impairment

AU - Tatsugami, Katsunori

AU - Oya, Mototsugu

AU - Kabu, Koki

AU - Akaza, Hideyuki

PY - 2018/4/10

Y1 - 2018/4/10

N2 - Background: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. Methods: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m2. Background factors considered to affect prognosis were well balanced by propensity score matching between the groups. Demographics, dose modification, adverse events, tumour response, progression-free survival, and renal function (eGFR) were evaluated. Results: Among 935 and 2008 patients with an eGFR of < 45 and ≥45, respectively, 613 pairs were matched. The mean starting dose was significantly lower in patients with an eGFR of < 45; however, the mean daily dose, median treatment duration, progression-free survival, and tumour response were similar between the groups. In terms of safety, no significant differences were found in serious adverse events, although cytopaenia (16.6% vs 10.6%) and renal dysfunction (4.4% vs 0.7%) were higher in patients with an eGFR of < 45 than ≥45 in all adverse events. There were also no differences in dose modification, including dose reduction, dose interruption, and treatment discontinuation. Conclusion: Throughout the 12-month observation period, sorafenib in patients with an eGFR of < 45 and ≥45 showed similar safety and efficacy, and treatment was continued without affecting renal function.

AB - Background: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. Methods: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m2. Background factors considered to affect prognosis were well balanced by propensity score matching between the groups. Demographics, dose modification, adverse events, tumour response, progression-free survival, and renal function (eGFR) were evaluated. Results: Among 935 and 2008 patients with an eGFR of < 45 and ≥45, respectively, 613 pairs were matched. The mean starting dose was significantly lower in patients with an eGFR of < 45; however, the mean daily dose, median treatment duration, progression-free survival, and tumour response were similar between the groups. In terms of safety, no significant differences were found in serious adverse events, although cytopaenia (16.6% vs 10.6%) and renal dysfunction (4.4% vs 0.7%) were higher in patients with an eGFR of < 45 than ≥45 in all adverse events. There were also no differences in dose modification, including dose reduction, dose interruption, and treatment discontinuation. Conclusion: Throughout the 12-month observation period, sorafenib in patients with an eGFR of < 45 and ≥45 showed similar safety and efficacy, and treatment was continued without affecting renal function.

KW - Advanced RCC

KW - EGFR

KW - Propensity score matching

KW - Real-world data

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85045200121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045200121&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24779

DO - 10.18632/oncotarget.24779

M3 - Article

AN - SCOPUS:85045200121

VL - 9

SP - 19406

EP - 19414

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -